SCHEMBL365988

SCHEMBL365988

O=C(Cn1ccnc1[N+](=O)[O-])NCC(F)(F)C(F)(F)F

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.65
THRB P10828 1/20 0.65
CYP2C19 P33261 1/20 0.65
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.60
OPRK1 P41145 1/20 0.60
CA12 O43570 5/20 0.55
CA1 P00915 5/20 0.55
CA2 P00918 5/20 0.55
CA9 Q16790 5/20 0.55
KMT2A Q03164 1/20 0.43
TYMP P19971 3/20 0.38
NOS1 P29475 1/20 0.35
F2 P00734 1/20 0.33
FPR2 P25090 1/20 0.32
ELANE P08246 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29415206 1.00 LMNA (0.65) LMNATHRBCYP2C19CYP3A4CYP2D6
SCHEMBL367133 0.90 LMNA (0.68) LMNATHRBCYP2C19CYP3A4CYP2D6
SCHEMBL15610852 0.88 LMNA (0.65) LMNATHRBCYP2C19CYP3A4CYP2D6
SCHEMBL14023821 0.85 LMNA (0.62) LMNATHRBCYP2C19CYP3A4CYP2D6
SCHEMBL14023806 0.85 LMNA (0.68) LMNATHRBCYP2C19CYP3A4CYP2D6
SCHEMBL2830638 0.82 LMNA (0.73) LMNATHRBCYP2C19CYP3A4CYP2D6
SCHEMBL15024639 0.81 LMNA (0.80) LMNATHRBCYP2C19CYP3A4CYP2D6
SCHEMBL368130 0.81 LMNA (0.78) LMNATHRBCYP2C19CYP3A4CYP2D6
SCHEMBL367605 0.81 LMNA (0.62) LMNATHRBCYP2C19CYP3A4CYP2D6
SCHEMBL3915318 0.80 LMNA (0.68) LMNATHRBCYP2C19CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1202945-B1 METHODS FOR PREPARING PERFLUORINATED [18 F]-RADIOLABELLED NITROIMIDAZOLE DERIVATIVES FOR CELLULAR HYPOXIA DETECTION UNIV CATHOLIQUE LOUVAIN (BE) 2005-08-17 EP claimed
EP-1202945-A1 METHODS FOR PREPARING PERFLUORINATED [18 F]-RADIOLABELLED NITROIMIDAZOLE DERIVATIVES FOR CELLULAR HYPOXIA DETECTION UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2002-05-08 EP claimed
WO-2001012575-A1 METHODS FOR PREPARING PERFLUORINATED [18F]-RADIOLABELLED NITROIMIDAZOLE DERIVATIVES FOR CELLULAR HYPOXIA DETECTION UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2001-02-22 WO claimed
WO-2026102212-A1 MACROCYCLIC MCL-1 INHIBITORS VANDERBILT UNIVERSITY (US) 2026-05-15 WO disclosed
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 US disclosed
US-20250340519-A1 RADIOLABELLED COMPOUND OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2025-11-06 US disclosed
US-12448388-B2 PRMT5 inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2025-10-21 US disclosed
EP-4624459-A2 RADIOLABELLED COMPOUND Oxford University Innovation Limited (GB) 2025-10-01 EP disclosed
CN-119679042-A Enzymatic hydrolysis biomass feed, method for preparing feed by using edible fungus enzymatic hydrolysis biomass and application of feed 南京高新工大生物技术研究院有限公司 2025-03-25 CN disclosed
CN-119613752-A Preparation method for constructing supermolecular polymer gel based on reaction of column [5] arene and crown ether 江西理工大学 2025-03-14 CN disclosed
US-20240398799-A1 COMPOSITIONS AND METHODS FOR GENERATING SYNTHETIC LETHALITY IN TUMORS ENGINE BIOSCIENCES PTE. LTD. (SG) 2024-12-05 US disclosed
US-6252087-B1 COMPLEXING WITH A PROTEIN THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2001-06-26 US disclosed
US-6218179-B1 NUCLEOTIDE SEQUENCES CODING HUMAN METALLOTHIONEIN REGULATORY SEQUENCES; FOR REDUCING ISCHEMIC INJURY TO A CELL EXPOSED TO HYPOXIC CONDITIONS SRI INTERNATIONAL 2001-04-17 US disclosed
US-5843404-A Immunogenic conjugates of nitroaromatic compounds and proteins; monoclonal antibodies specific for nitroaromatic compounds , their protein conjugates TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 1998-12-01 US disclosed
EP-0799308-A1 TISSUE SPECIFIC HYPOXIA REGULATED THERAPEUTIC CONSTRUCTS SRI INTERNATIONAL (US) 1997-10-08 EP disclosed
EP-0669913-A4 DETECTION OF HYPOXIA. UNIV PENNSYLVANIA (US) 1996-08-21 EP disclosed
US-5540908-A DETECTION OF OXYGEN DEPRIVATION USING IMMUNOHISTOLOGICAL METHODS THE TRUSTEES OF THE UNIV. OF PENNSYLVANIA (US) 1996-07-30 US disclosed
WO-1996020276-A1 TISSUE SPECIFIC HYPOXIA REGULATED THERAPEUTIC CONSTRUCTS SRI INTERNATIONAL (US) 1996-07-04 WO disclosed
EP-0669913-A1 DETECTION OF HYPOXIA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 1995-09-06 EP disclosed
WO-1994011348-A1 DETECTION OF HYPOXIA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 1994-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT1, PRMT5, PRMT6 LMNA 1373/4885THRB 1508/4885CYP2C19 4791/4885
US-20250340519-A1 RADIOLABELLED COMPOUND PARP3, PARP2, PARP1 LMNA 4486/4885THRB 2271/4885CYP2C19 452/4885
US-12448388-B2 PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT9 LMNA 2517/4885THRB 3384/4885CYP2C19 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.